← Back to Search

Hormone Therapy

Tamoxifen for Tumors (HORMONET Trial)

Phase 2

Waitlist Available

Led By Jonathan R Strosberg, MD

Research Sponsored by AC Camargo Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 5 years

Awards & highlights

HORMONET Trial Summary

This trialwill study if Tamoxifen can help patients with neuroendocrine tumors and positive hormone expression.

Eligible Conditions

Tumors
Neuroendocrine Tumors

HORMONET Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Secondary outcome measures

Disease control rate

Incidence of Treatment-related Adverse Events

Progression-free survival

+2 more

Other outcome measures

CTC positivity rate

PET-CT gallium-68 intake variation

PET-CT gallium-68 number variation

HORMONET Trial Design

1Treatment groups

Experimental Treatment

Group I: TamoxifenExperimental Treatment1 Intervention

The participants will receive tamoxifen 20mg orally once daily with a glass of water. Each cycle will be defined for 42 days (6 weeks).

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Tamoxifen

2005

Completed Phase 4

~30070

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

AC Camargo Cancer CenterLead Sponsor

27 Previous Clinical Trials

7,998 Total Patients Enrolled

H. Lee Moffitt Cancer Center and Research InstituteOTHER

542 Previous Clinical Trials

135,469 Total Patients Enrolled

1 Trials studying Tumors

9 Patients Enrolled for Tumors

Jonathan R Strosberg, MDPrincipal InvestigatorH. Lee Moffitt Cancer Center and Research Institute

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What conditions does Tamoxifen usually address?

"Tamoxifen is a well-known treatment option for malignant neoplasms, ovarian cancer, and ovulation induction therapy."

Answered by AI

What adverse effects might be associated with Tamoxifen use?

"Tamoxifen has been awarded a safety rating of 2, as Phase 2 trials indicate the presence of some data points suggesting it is safe yet there are no evidentiary claims that its efficacy can be proven."

Answered by AI

Is this clinical investigation recruiting participants?

"Per the information displayed on clinicaltrials.gov, this particular trial is not actively seeking enrolment. It was initially posted in March 13th 2019 and last edited January 13rd 2023. However, there are a plethora of other studies currently recruiting participants - 2511 to be exact!"

Answered by AI

What other experiments regarding the efficacy of Tamoxifen have been conducted thus far?

"At this time, 69 studies are utilizing Tamoxifen as an experimental treatment with 22 of them being in their final stage. Most trials focused on the drug take place within Oregon and Ohio but there is a far reach with 7552 sites hosting related clinical trials."

Answered by AI

What is the utmost capacity of participants for this research project?

"This clinical trial is not presently enrolling new patients. It was originally posted on March 13th, 2019 and last updated on January 13th, 2023. If you are seeking alternative studies to participate in, there are currently 2442 active trials recruiting for those with progesterone receptor positive tumors; additionally, 69 trials using Tamoxifen have open enrolment slots available too."

Answered by AI

Recent research and studies

The LancetJournal

Carcinoid Tumour

Caplin, Martyn E, John R Buscombe, Andrew J Hilson, Alison L Jones, Anthony F Watkinson, and Andrew K Burroughs. 1998. “Carcinoid Tumour”. The Lancet. Elsevier BV. doi:10.1016/s0140-6736(98)02286-7.

Journal of Clinical OncologyJournal

Placebo-controlled, Double-blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors: A Report from the PROMID Study Group

Rinke, Anja, Hans-Helge Müller, Carmen Schade-Brittinger, Klaus-Jochen Klose, Peter Barth, Matthias Wied, Christina Mayer, et al.. 2009. “Placebo-controlled, Double-blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors: A Report from the PROMID Study Group”. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO). doi:10.1200/jco.2009.22.8510.

New England Journal of MedicineJournal

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

Yao, James C., Manisha H. Shah, Tetsuhide Ito, Catherine Lombard Bohas, Edward M. Wolin, Eric Van Cutsem, Timothy J. Hobday, et al.. 2011. “Everolimus for Advanced Pancreatic Neuroendocrine Tumors”. New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmoa1009290.

clinicaltrials.govStudy